Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

Gösta Gahrton, Sante Tura, Per Ljungman, Joan Bladé, Lena Brandt, Michele Cavo, Thierry Façon, Alois Gratwohl, Anton Hagenbeek, Peter Jacobs, Antonio De Laurenzi, M. Van Lint, Mauricette Michallet, Jukka Nikoskelainen, Josy Reiffers, Diana Samson, Leo Verdonck, Theo De Witte, Liisa Volin

Research output: Contribution to journalArticle

Abstract

Purpose: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. Patients and Methods: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. Results: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse- free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low β2-microglobulin level (<4 g/L) also tended to have a favorable prognostic impact. The most important posttransplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. Conclusion: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.

Original languageEnglish
Pages (from-to)1312-1322
Number of pages11
JournalJournal of Clinical Oncology
Volume13
Issue number6
Publication statusPublished - Jun 1995

Fingerprint

Homologous Transplantation
Multiple Myeloma
Bone Marrow Transplantation
Survival
Survival Rate
Graft vs Host Disease
Tumor Burden
Immunoglobulin A
Registries
Siblings
Therapeutics
Tissue Donors
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gahrton, G., Tura, S., Ljungman, P., Bladé, J., Brandt, L., Cavo, M., ... Volin, L. (1995). Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology, 13(6), 1312-1322.

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. / Gahrton, Gösta; Tura, Sante; Ljungman, Per; Bladé, Joan; Brandt, Lena; Cavo, Michele; Façon, Thierry; Gratwohl, Alois; Hagenbeek, Anton; Jacobs, Peter; De Laurenzi, Antonio; Van Lint, M.; Michallet, Mauricette; Nikoskelainen, Jukka; Reiffers, Josy; Samson, Diana; Verdonck, Leo; De Witte, Theo; Volin, Liisa.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 06.1995, p. 1312-1322.

Research output: Contribution to journalArticle

Gahrton, G, Tura, S, Ljungman, P, Bladé, J, Brandt, L, Cavo, M, Façon, T, Gratwohl, A, Hagenbeek, A, Jacobs, P, De Laurenzi, A, Van Lint, M, Michallet, M, Nikoskelainen, J, Reiffers, J, Samson, D, Verdonck, L, De Witte, T & Volin, L 1995, 'Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1312-1322.
Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. Journal of Clinical Oncology. 1995 Jun;13(6):1312-1322.
Gahrton, Gösta ; Tura, Sante ; Ljungman, Per ; Bladé, Joan ; Brandt, Lena ; Cavo, Michele ; Façon, Thierry ; Gratwohl, Alois ; Hagenbeek, Anton ; Jacobs, Peter ; De Laurenzi, Antonio ; Van Lint, M. ; Michallet, Mauricette ; Nikoskelainen, Jukka ; Reiffers, Josy ; Samson, Diana ; Verdonck, Leo ; De Witte, Theo ; Volin, Liisa. / Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1312-1322.
@article{05351c7325c14e41adb173f2acad2db3,
title = "Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma",
abstract = "Purpose: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. Patients and Methods: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. Results: Following BMT, 44{\%} of all patients and 60{\%} of assessable patients entered complete remission. The overall actuarial survival rate was 32{\%} at 4 years and 28{\%} at 7 years. The overall relapse- free survival rate of 72 patients who were in complete remission after BMT was 34{\%} at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41{\%} at 4 years), stage I disease at diagnosis (52{\%} at 4 years), one line of previous treatment (42{\%} at 4 years), and being in complete remission before conditioning (64{\%} at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low β2-microglobulin level (<4 g/L) also tended to have a favorable prognostic impact. The most important posttransplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. Conclusion: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.",
author = "G{\"o}sta Gahrton and Sante Tura and Per Ljungman and Joan Blad{\'e} and Lena Brandt and Michele Cavo and Thierry Fa{\cc}on and Alois Gratwohl and Anton Hagenbeek and Peter Jacobs and {De Laurenzi}, Antonio and {Van Lint}, M. and Mauricette Michallet and Jukka Nikoskelainen and Josy Reiffers and Diana Samson and Leo Verdonck and {De Witte}, Theo and Liisa Volin",
year = "1995",
month = "6",
language = "English",
volume = "13",
pages = "1312--1322",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

AU - Gahrton, Gösta

AU - Tura, Sante

AU - Ljungman, Per

AU - Bladé, Joan

AU - Brandt, Lena

AU - Cavo, Michele

AU - Façon, Thierry

AU - Gratwohl, Alois

AU - Hagenbeek, Anton

AU - Jacobs, Peter

AU - De Laurenzi, Antonio

AU - Van Lint, M.

AU - Michallet, Mauricette

AU - Nikoskelainen, Jukka

AU - Reiffers, Josy

AU - Samson, Diana

AU - Verdonck, Leo

AU - De Witte, Theo

AU - Volin, Liisa

PY - 1995/6

Y1 - 1995/6

N2 - Purpose: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. Patients and Methods: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. Results: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse- free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low β2-microglobulin level (<4 g/L) also tended to have a favorable prognostic impact. The most important posttransplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. Conclusion: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.

AB - Purpose: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. Patients and Methods: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. Results: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse- free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low β2-microglobulin level (<4 g/L) also tended to have a favorable prognostic impact. The most important posttransplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. Conclusion: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.

UR - http://www.scopus.com/inward/record.url?scp=0029039069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039069&partnerID=8YFLogxK

M3 - Article

C2 - 7751876

AN - SCOPUS:0029039069

VL - 13

SP - 1312

EP - 1322

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -